{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05673018",
            "orgStudyIdInfo": {
                "id": "GRAIL-MA-002"
            },
            "organization": {
                "fullName": "GRAIL, LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "Galleri in the Medicare Population",
            "officialTitle": "REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "galleri-in-the-medicare-population"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-12",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2030-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2030-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-12-07",
            "studyFirstSubmitQcDate": "2023-01-04",
            "studyFirstPostDateStruct": {
                "date": "2023-01-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "GRAIL, LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true,
            "isUnapprovedDevice": true
        },
        "descriptionModule": {
            "briefSummary": "This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri\u00ae, a blood-based multi-cancer early detection (MCED) test. The study will seek to enroll approximately 20% of the study participants from under-represented minority populations (e.g., racial / ethnic minority groups, socioeconomically disadvantaged populations, rural populations)."
        },
        "conditionsModule": {
            "conditions": [
                "Cancer"
            ],
            "keywords": [
                "ctDNA, Circulating tumor DNA, Screening, Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "The parallel arm is a passively-enrolled contemporaneous comparator cohort of Medicare beneficiaries who receive usual care without MCED screening.",
                "primaryPurpose": "SCREENING",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 50000,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "(Galleri + UC)",
                    "type": "EXPERIMENTAL",
                    "description": "Medicare beneficiaries who receive the Galleri test plus usual care (Galleri + UC).",
                    "interventionNames": [
                        "Device: Multi-Cancer Early Detection Test (Galleri\u00ae)"
                    ]
                },
                {
                    "label": "(UC) alone",
                    "type": "NO_INTERVENTION",
                    "description": "Passively-enrolled Contemporaneous Comparator Arm of Medicare beneficiaries who receive usual care (UC) alone."
                }
            ],
            "interventions": [
                {
                    "type": "DEVICE",
                    "name": "Multi-Cancer Early Detection Test (Galleri\u00ae)",
                    "description": "Blood collection and multi-cancer early detection testing with return of results.",
                    "armGroupLabels": [
                        "(Galleri + UC)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence rates of stage IV cancers",
                    "timeFrame": "Up to 3 Years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Safety: Number and type of invasive procedures performed to evaluate a cancer signal detected test result",
                    "timeFrame": "Up to 3 Years"
                },
                {
                    "measure": "Galleri test performance in the Galleri + UC arm",
                    "timeFrame": "Up to 3 Years"
                },
                {
                    "measure": "Adherence to guideline-recommended cancer screening in the Galleri+UC arm and UC arm over time",
                    "timeFrame": "Up to 3 Years"
                },
                {
                    "measure": "Healthcare resource utilization associated with cancer diagnostic evaluations in the Galleri+UC arm and UC arm",
                    "timeFrame": "Up to 3 Years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nFor Galleri + UC (Galleri-Tested Arm):\n\nParticipants are eligible to be included in the study only if all of the following criteria apply:\n\n* Aged \u226550 years with Medicare coverage,\n* Eligible to receive the Galleri test, based on a determination by the study investigator or designee that the test is clinically appropriate,\n* Capable of giving informed consent that is legally effective (consent provided by a legally authorized representative is not permitted in this protocol), and\n* Able to comprehend and respond to questions in participant questionnaires. Comprehension level is determined by the study investigator or designee.\n\nFor UC (Not Galleri-tested Arm):\n\n* Aged \u2265 50 years with Medicare coverage,\n* Have had \u2265 1 UC visit\n\nExclusion Criteria:\n\nFor Galleri + UC (Galleri-Tested Arm):\n\n* Having had a previous Galleri test not associated with this study.\n* Undergoing clinical evaluation for symptoms suspicious for cancer.\n* Personal history of invasive solid tumor or hematologic malignancy, diagnosed within the 3 years prior to expected enrollment date, or diagnosed greater than 3 years prior to expected enrollment date and never treated.\n* Individuals with a diagnosis of non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin are not excluded.\n* Prior/Concurrent Concomitant Therapy (Medications/Treatments):\n* Definitive treatment for invasive solid tumor or hematologic malignancy within the 3 years prior to expected enrollment date.\n* Adjuvant hormone therapy for cancer (i.e., for breast or prostate cancer) is not an exclusion criterion.\n* Current pregnancy\n* Individuals who will not be able to comply with the protocol procedures.\n* Individuals who are not currently registered patients at a participating center.\n* Previous or current employees or contractors of GRAIL.\n\nFor UC (Not Galleri-tested Arm):\n\n* Undergoing or referred for diagnostic evaluation due to clinical suspicion for cancer (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality).\n* Personal history of invasive solid tumor or hematologic malignancy, diagnosed within the 3 years prior to expected enrollment date, or diagnosed greater than 3 years prior to expected enrollment date and never treated.\n* Individuals with a diagnosis of non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin are not excluded.\n* Prior/Concurrent Concomitant Therapy (Medications/Treatments):\n* Definitive treatment for invasive solid tumor or hematologic malignancy within the 3 years prior to expected enrollment date.\n* Adjuvant hormone therapy for cancer (e.g. for breast or prostate cancer) is not an exclusion criterion.\n* Current pregnancy.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "50 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "locations": [
                {
                    "facility": "Community Health Network",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46256",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joy Koglin",
                            "role": "CONTACT",
                            "phone": "317-621-7724",
                            "email": "jkoglin@ecommunity.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        }
    },
    "hasResults": false
}